Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

CAMBRIDGE, Mass., April 24, 2024 -- Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1...

Related Keywords

Chad ,Cambridge ,Cambridgeshire ,United Kingdom ,Chicago ,Illinois ,United States ,American ,Jeffrey Jones ,Rose Weldon ,Ignacio Melero ,American Society Of Clinical Oncology ,Cullinan Therapeutics Inc ,Linkedin ,Exchange Commission ,Nasdaq ,Clinical Oncology ,Annual Meeting ,Chief Medical Officer ,Developmental Therapeutics ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,